Astellas Gets OK For $98M Deal In Prograf Antitrust MDL
A Massachusetts federal judge on Wednesday signed off on a $98 million deal between buyers of organ transplant anti-rejection drug Prograf and Astellas Pharma US Inc., ending allegations Astellas delayed entry...To view the full article, register now.
Already a subscriber? Click here to view full article